Antibiofilm agent-19
Antibiofilm agent-19 is an antibiofilm agent with iron-chelating activity. Antibiofilm agent-19 potently inhibits biofilm formation by wild-type PAO1 and the hyper-biofilm mutant strain PAO1-ΔwspF. Antibiofilm agent-19 promotes the formation of c-di-GMP G-quadruplexes and disrupts iron acquisition systems. It can be used in studies on antibacterial adjuvants.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C19H21IN2O3S
- Masse moléculaire:484.35
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
Antibiofilm agent-19 (compound 11f) (0.156-2.5 μM; 24 h) potently inhibits biofilm formation by P. aeruginosa PAO1-ΔwspF (at 0.156 μM) and wild-type PAO1 (at 2.5 μM) without affecting bacterial growth[1].
Antibiofilm agent-19 (0-2.5 μM; 12-16 h) reduces the production of extracellular polymeric substances in P. aeruginosa, with the strongest efficacy observed in the PAO1-ΔwspF strain with high c-di-GMP levels[1].
Antibiofilm agent-19 (0.125-50 μM; 24 h) disrupts iron homeostasis in P. aeruginosa by promoting siderophore secretion, and this effect is reversed by the addition of excess Fe3+ [1].
Antibiofilm agent-19 (6.25-200 μM; 24 h) exhibits excellent biocompatibility, with no significant cytotoxicity against Vero cells or RAW264.7 macrophages even at concentrations as high as 200 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Vero cells, RAW264.7 macrophages
-
Concentration:6.25, 12.5, 25, 50, 100 and 200 μM
-
Incubation Time:24 h
-
Result:Resulted in >90% viability in both Vero cells and RAW264.7 macrophages across all tested concentrations, with no observable morphological alterations.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Galleria mellonella infected with P. aeruginosa strains PAO1 (wild-type)[1]
-
Dosage:2.5 μM (co-administered with Ciprofloxacin 0.001 mg/mL or Tobramycin 0.0025 mg/mL)
-
Administration:intracoelomic injection; single dose
-
Result:Achieved >70% larval survival at day 5 when co-administered with tobramycin, compared to 40% survival with tobramycin alone.
Achieved nearly 80% larval survival at day 5 when co-administered with ciprofloxacin, a statistically significant improvement over ciprofloxacin alone.
-
Animal Model:Galleria mellonella infected with P. aeruginosa strains PAO1-ΔwspF (high-biofilm mutant)[1]
-
Dosage:0.156 μM (co-administered with Ciprofloxacin 0.001 mg/mL or Tobramycin 0.0025 mg/mL)
-
Administration:intracoelomic injection; single dose
-
Result:Significantly improved larval survival rates at day 5 when co-administered with either tobramycin or ciprofloxacin compared to the corresponding antibiotic alone.
Chemical Information
-
Masse moléculaire 484.35
-
Formule C19H21IN2O3S
-
SMILES
C[N+]1=C(SC2=CC=CC=C21)/C=C/C(N(C=C3O)CCCOC)=CC3=O.[I-]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antibiofilm agent-19 Related Classifications
HY-181713 Related Classifications
Powered by Bioz